Casi pharmaceuticals, receives nasdaq deficiency notice

Rockville, md. and beijing, jan. 3, 2022 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that on december 30, 2021, casi received a deficiency letter from the listing qualifications department (the "staff") of the nasdaq stock market ("nasdaq") notifying casi that, for the previous 30 consecutive business days, the bid price of casi's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the nasdaq capital market pursuant to nasdaq listing rule 5550(a)(2) (the "bid price rule").
CASI Ratings Summary
CASI Quant Ranking